Science
Prozac use for childhood depression skewed by single flawed medical trial
Publication: Nature
Author: Richard Van Noorden
Source published: 02/10/2026, 00:00:00 UTC
Briefing created: 03/10/2026, 07:53:17 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 02/10/2026, 14:50:25 UTC.
Briefings
A single small clinical trial conducted in Iran in 2026 suggested that Prozac is effective for childhood depression, potentially influencing broader medical consensus. This finding emerged from a study with limited sample size and methodological concerns, prompting researchers to question the reliability of the results before larger, more rigorous trials could confirm or refute the initial findings.
Key points
- A small clinical trial in Iran in 2026 suggested Prozac is effective for childhood depression, potentially influencing medical consensus.
- The initial study had limited sample size and methodological concerns, prompting researchers to question the reliability of the results.
Context and limitations
The initial study had a small sample size and methodological concerns, limiting the generalizability of the findings.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 03/10/2026, 07:53:17 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeidmp7ffmtiwuw35lma67vpau6kqojiik5xp4fwddaifondyidt2ia